NICE says yes to Novartis’ Rydapt for rare blood disorderNovartis’ Rydapt has become the first and only licensed treatment for rare and life-threatening blood disorder systemic mastocytosis Share XNICE says yes to Novartis’ Rydapt for rare blood disorderhttps://pharmaphorum.com/news/nice-says-yes-to-novartis-rydapt-for-rare-blood-disorder/
Blueprint’s latest approval for Ayvakit sets up clash with NovartisBlueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM), Share XBlueprint’s latest approval for Ayvakit sets up clash with Novartishttps://pharmaphorum.com/news/blueprints-latest-approval-for-ayvakit-sets-up-clash-with-novartis/
